Core Viewpoint - Oruka Therapeutics is set to present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its focus on developing novel biologics for chronic skin diseases, particularly plaque psoriasis [1]. Company Overview - Oruka Therapeutics is a clinical stage biotechnology company dedicated to creating innovative biologics aimed at establishing a new standard for treating chronic skin diseases [2]. - The company's mission is to provide patients with chronic skin diseases, such as plaque psoriasis, the highest possible freedom from their condition, targeting high rates of complete disease clearance with infrequent dosing, potentially once or twice a year [2]. - Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies engineered by Paragon Therapeutics, which target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases [2].
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference